PharmaVoice

AUGUST 7, 2025

In a recently revealed study, Tagrisso with chemotherapy demonstrated long-term overall survival benefit in patients with EGFR-mutated non-small cell lung cancer. AstraZeneca has a goal to treat more than half of all people with lung cancer with one or more of its drugs by 2030. This interview has been edited for brevity and style.

Chemotherapy

BioPharma Dive

AUGUST 8, 2025

In a final analysis from a late-stage study, a combination of Tagrisso and chemotherapy meaningfully extended survival in patients with EGFR-mutated non-small cell lung cancer. AstraZeneca has a goal to treat more than half of all people with lung cancer with one or more of its drugs by 2030. How will you accomplish that?

Drug Pricing

STAT

NOVEMBER 12, 2024

  The medicine, datopotamab deruxtecan, or Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies have been pouring investments into. But full trial data published in September showed Dato-DXd did not outperform standard chemotherapy on overall survival. 

Chemotherapy

Express Pharma

SEPTEMBER 18, 2024

billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. Pluvicto is indicated for metastatic CRPC (mCRPC) patients previously treated with ADT and taxane chemotherapy. billion by 2030. bn in sales by 2030 appeared first on Express Pharma.

Chemotherapy

pharmaphorum

OCTOBER 6, 2022

Fresh with a new brand identity, the France-headquartered pharma group has pledged to grow its oncology sales from its current objective of €1 billion in 2025 to €3 billion in 2030, continuing a diversification of its business from its traditional focus on cardiovascular diseases. billion and $1.8 billion, respectively, five years later.

Generic Medicine

STAT

NOVEMBER 12, 2024

The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily. AstraZeneca, which is partnered with Daiichi Sankyo on the drug, has cited Dato-DXd as one of the products that will help it nearly double revenue to $80 billion by 2030.

Chemotherapy

Express Pharma

SEPTEMBER 19, 2023

Venus Remedies has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs. per cent from 2021 to 2030. With this, the company has secured 511 marketing approvals for its oncology products across 66 countrles. billion in 2021 and is projected to reach $536.01

Chemotherapy

Express Pharma

JUNE 1, 2023

Venus Remedies secured a marketing authorisation from the largest market in the Gulf Cooperation Council (GCC) region for Docetaxel, a chemotherapy drug. The $102-billion global Docetaxel market is projected to grow to $184 billion by year 2030 at a CAGR of 10.22 The marketing approval for Docetaxel from Saudi Arabia, a $7.8-billion

Chemotherapy

pharmaphorum

JUNE 8, 2021

The entire APAC region already accounts for 30% of all global pharma spending, and within these markets national healthcare expenditure is expected to increase threefold to over $2 trillion by 2030. Chemotherapy still accounted for 72.6% million in 2030. of the oncology market in China in 2019, compared to 17.1%

Chemotherapy

Express Pharma

NOVEMBER 20, 2023

The approval was based on a Phase II clinical trial as second-line therapy after prior asparaginase-based chemotherapy or chemo-radiotherapy for the treatment of adult patients with r/r ENKTL. GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China.

Chemotherapy

Express Pharma

MAY 6, 2024

This antibody-directed killing of cancer has the potential to substantially increase the outcomes of current cancer therapies, such as chemotherapy. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, via a linker, to selectively target and eliminate cancerous cells. billion in 2023.

Chemotherapy

Big Molecule Watch

DECEMBER 16, 2024

UDENYCA , the only biosimilar to Amgens NEULASTA in the United States, is administered the day after chemotherapy treatment to decrease the incidence of infection by febrile neutropenia. (Intas), announced an agreement to acquire Coherus BioSciences, Inc.s UDENYCA (pegfilgrastim-cbqv) business.

Biosimilars

pharmaphorum

MARCH 8, 2022

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy. appeared first on.

Chemotherapy

pharmaphorum

JUNE 6, 2022

months, compared to 4 months with chemotherapy, a 34% improvement. “The standard of care is…limited to sequential single agent chemotherapy, with declining response rates, disease control and quality of life,” remarked Dr Hope Rugo of California San Francisco Comprehensive Cancer Centre, the trial’s lead investigator.

Chemotherapy